52 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
with the SEC. We have not, and Leerink Partners has not, authorized anyone to provide you with different information. We take no responsibility for, and can … . The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation … ) on the number or dollar amount of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility
6-K
EX-99.3
IFRX
InflaRx N.V.
1 Nov 23
Current report (foreign)
8:04am
responsibility for the content of this work lies with InflaRx.
Contacts:
InflaRx N.V.
MC Services AG
Email: IR@inflarx.de
Katja Arnold, Laurie Doyle
6-K
EX-99.1
IFRX
InflaRx N.V.
30 Aug 23
Current report (foreign)
8:00am
work described herein is partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID). All responsibility for the content
6-K
EX-99.2
yug7hho
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.3
bj29cv8wdnkb3u moc2
10 Aug 23
Report of Foreign Private Issuer
8:00am
424B5
snftgl5e4dw4s
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
EX-4.3
8a7 nitro8fqt9q
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-5.2
gqi6ic
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.2
8ax8v860qiq1vw
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
4ed4nol
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
gx4xo
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-99.3
bxgt5g09
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
d40bvu6
13 Apr 23
Current report (foreign)
4:01pm
424B5
unohu4t158n gnfx95
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
c687ryr
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
hkl r8sf7f6
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.1
lxe byoxqrupx
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.4
zvwj0spb
9 Nov 22
Current report (foreign)
7:52am